

New Biological Insights and Recent Therapeutic Advances in the Management of Acute and Chronic Leukemias and Myelodysplastic Syndromes

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following is an adverse event associated with idelalisib treatment in patients with chronic lymphocytic leukemia (CLL)?
 - a. Transaminitis
 - b. Pneumonitis
 - c. Colitis
 - d. Both a and b
 - e. All of the above
2. The improvement in progression-free survival when sorafenib was added to standard induction therapy for patients aged 60 years or younger with newly diagnosed acute myeloid leukemia (AML) was restricted to patients with FLT3-ITD mutation-positive disease.
 - a. True
 - b. False
3. For elderly patients with AML who were not eligible for chemotherapy, the addition of the polo-like kinase inhibitor volasertib to low-dose cytarabine improved efficacy in terms of _____.
 - a. Response rate
 - b. Median event-free survival
 - c. Median overall survival
 - d. Both b and c
 - e. All of the above
4. Lenalidomide therapy did not result in improved rates of transfusion independence when compared to placebo for patients with lower-risk myelodysplastic syndromes lacking the deletion 5q karyotypic abnormality and unresponsive or refractory to erythropoiesis stimulating agents.
 - a. True
 - b. False
5. For patients with previously treated acute lymphoblastic leukemia (ALL) and remaining minimal residual disease, the bispecific T-cell engaging monoclonal antibody _____ resulted in high complete response rates in the bone marrow.
 - a. Obinutuzumab
 - b. Blinatumomab
 - c. Ofatumumab
6. Intensive treatment regimens developed for pediatric patients with ALL have also been shown to be efficacious in older adolescents and young adults with this disease.
 - a. True
 - b. False
7. _____ is an adverse event associated with the protein synthesis inhibitor omacetaxine mepesuccinate in the management of chronic myeloid leukemia.
 - a. Gastrointestinal toxicity
 - b. Cytopenia
 - c. Both a and b
 - d. None of the above
8. The achievement of partial responses with lymphocytosis in patients with CLL may be observed as part of the clinical pattern of response associated with _____ treatment.
 - a. Single-agent idelalisib
 - b. Single-agent ibrutinib
 - c. Both a and b